Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy

clinical trial

Details

Instance of: clinical trial
Start time: May 2009
End time: July 2015
Country: United States
Main subject: Epstein–Barr virus infection
clinical trial phase: phase I clinical trial
minimum age: 3
number of participants: 20
short name: HERCREEM
study type: interventional study
title: Administration of Her2 Chimeric Receptor and TGFbeta Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects With Advanced Her2 Positive Malignancy (HERCREEM)

Nothing in the MetaHistoryBook collection references this item yet.